Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Lessened by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,758 shares of the biotechnology company’s stock after selling 177 shares during the period. Orion Portfolio Solutions LLC’s holdings in Sarepta Therapeutics were worth $1,219,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC raised its holdings in Sarepta Therapeutics by 14.2% during the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after buying an additional 543,143 shares in the last quarter. Wellington Management Group LLP raised its holdings in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in Sarepta Therapeutics by 9.2% during the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock valued at $94,148,000 after buying an additional 63,437 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in Sarepta Therapeutics by 6.3% during the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock valued at $101,858,000 after buying an additional 37,940 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new position in Sarepta Therapeutics during the third quarter valued at about $79,425,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Down 0.6 %

NASDAQ SRPT opened at $123.71 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock’s 50 day moving average is $123.12 and its two-hundred day moving average is $131.43. The company has a market capitalization of $11.82 billion, a price-to-earnings ratio of 98.97 and a beta of 0.77. Sarepta Therapeutics, Inc. has a 1-year low of $89.92 and a 1-year high of $173.25.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SRPT. Jefferies Financial Group began coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 target price on the stock. StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Evercore ISI cut their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Needham & Company LLC dropped their price objective on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a research note on Wednesday, November 27th. Finally, UBS Group lifted their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $178.71.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.